STOCK TITAN

[Form 4] Bausch + Lomb Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

EVP of R&D and CMO Yehia Hashad filed a Form 4 for Bausch + Lomb (BLCO). On 07/25/2025 he disposed of 2,841 common shares at an accounting price of $14.32 under transaction code F, indicating shares were withheld solely to cover payroll-tax obligations triggered by the vesting of restricted share units. The disposition was not an open-market sale and does not change the executive’s economic exposure. After the withholding, Hashad directly owns 116,739 BLCO shares. No derivative securities were reported. The filing signals continued sizable insider ownership and appears routine rather than indicative of a change in insider sentiment.

Il vicepresidente esecutivo di R&S e CMO Yehia Hashad ha presentato un Modulo 4 per Bausch + Lomb (BLCO). Il 25/07/2025 ha ceduto 2.841 azioni ordinarie a un prezzo contabile di 14,32 $ con il codice transazione F, indicando che le azioni sono state ritenute esclusivamente per coprire obblighi fiscali sul reddito da lavoro derivanti dalla maturazione delle unità azionarie vincolate. La cessione non è stata una vendita sul mercato aperto e non modifica l’esposizione economica dell’esecutivo. Dopo la trattenuta, Hashad possiede direttamente 116.739 azioni BLCO. Non sono stati segnalati strumenti derivati. La comunicazione evidenzia una consistente partecipazione interna e appare di routine, senza indicare un cambiamento nel sentiment degli insider.

El vicepresidente ejecutivo de I+D y CMO Yehia Hashad presentó un Formulario 4 para Bausch + Lomb (BLCO). El 25/07/2025 dispuso de 2,841 acciones comunes a un precio contable de $14.32 bajo el código de transacción F, indicando que las acciones fueron retenidas únicamente para cubrir obligaciones fiscales sobre nómina generadas por la consolidación de unidades restringidas de acciones. La disposición no fue una venta en mercado abierto y no cambia la exposición económica del ejecutivo. Después de la retención, Hashad posee directamente 116,739 acciones BLCO. No se reportaron valores derivados. La presentación señala una continua participación significativa de los insiders y parece rutinaria, sin indicar un cambio en el sentimiento interno.

R&D 부사장 겸 CMO인 Yehia Hashad가 Bausch + Lomb (BLCO)에 대한 Form 4를 제출했습니다. 2025년 7월 25일, 그는 회계 가격 $14.322,841 보통주를 거래 코드 F로 처분했으며, 이는 제한 주식 단위의 권리 확정으로 인해 발생한 급여세 의무를 충당하기 위해 주식이 단지 원천징수되었음을 나타냅니다. 이 처분은 공개 시장 판매가 아니며 경영진의 경제적 노출에 변화를 주지 않습니다. 원천징수 후 Hashad는 직접 116,739 BLCO 주식을 보유하고 있습니다. 파생 증권은 보고되지 않았습니다. 이 제출은 지속적인 내부자 대규모 소유를 나타내며 내부자 심리 변화보다는 일상적인 것으로 보입니다.

Le vice-président exécutif de la R&D et CMO Yehia Hashad a déposé un formulaire 4 pour Bausch + Lomb (BLCO). Le 25/07/2025, il a cédé 2 841 actions ordinaires à un prix comptable de 14,32 $ sous le code de transaction F, indiquant que les actions ont été retenues uniquement pour couvrir les obligations fiscales liées à la paie déclenchées par l’acquisition des unités d’actions restreintes. La cession n’était pas une vente sur le marché ouvert et ne modifie pas l’exposition économique du dirigeant. Après cette retenue, Hashad détient directement 116 739 actions BLCO. Aucun instrument dérivé n’a été déclaré. Ce dépôt indique une importante détention interne continue et semble être une opération routinière plutôt qu’un signe d’évolution du sentiment des initiés.

Der EVP für F&E und CMO Yehia Hashad reichte ein Formular 4 für Bausch + Lomb (BLCO) ein. Am 25.07.2025 veräußerte er 2.841 Stammaktien zu einem Buchpreis von 14,32 $ unter Transaktionscode F, was darauf hinweist, dass die Aktien ausschließlich zur Deckung von Lohnsteuerverpflichtungen einbehalten wurden, die durch die Vesting von Restricted Share Units ausgelöst wurden. Die Veräußerung war kein Verkauf am offenen Markt und ändert nicht die wirtschaftliche Beteiligung des Executives. Nach der Einbehaltung besitzt Hashad direkt 116.739 BLCO-Aktien. Es wurden keine Derivate gemeldet. Die Meldung signalisiert weiterhin eine erhebliche Insiderbeteiligung und erscheint routinemäßig, ohne auf eine Änderung der Insider-Stimmung hinzudeuten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding entry; neutral to valuation.

The F-code tells investors the 2,841 shares were automatically withheld at vesting, avoiding open-market activity. The executive still controls 116.7k shares, preserving alignment with shareholders. Such small, non-discretionary dispositions rarely affect float or signal conviction. Therefore, market impact is neutral, though the filing confirms ongoing equity-based compensation and sizeable insider stake.

Il vicepresidente esecutivo di R&S e CMO Yehia Hashad ha presentato un Modulo 4 per Bausch + Lomb (BLCO). Il 25/07/2025 ha ceduto 2.841 azioni ordinarie a un prezzo contabile di 14,32 $ con il codice transazione F, indicando che le azioni sono state ritenute esclusivamente per coprire obblighi fiscali sul reddito da lavoro derivanti dalla maturazione delle unità azionarie vincolate. La cessione non è stata una vendita sul mercato aperto e non modifica l’esposizione economica dell’esecutivo. Dopo la trattenuta, Hashad possiede direttamente 116.739 azioni BLCO. Non sono stati segnalati strumenti derivati. La comunicazione evidenzia una consistente partecipazione interna e appare di routine, senza indicare un cambiamento nel sentiment degli insider.

El vicepresidente ejecutivo de I+D y CMO Yehia Hashad presentó un Formulario 4 para Bausch + Lomb (BLCO). El 25/07/2025 dispuso de 2,841 acciones comunes a un precio contable de $14.32 bajo el código de transacción F, indicando que las acciones fueron retenidas únicamente para cubrir obligaciones fiscales sobre nómina generadas por la consolidación de unidades restringidas de acciones. La disposición no fue una venta en mercado abierto y no cambia la exposición económica del ejecutivo. Después de la retención, Hashad posee directamente 116,739 acciones BLCO. No se reportaron valores derivados. La presentación señala una continua participación significativa de los insiders y parece rutinaria, sin indicar un cambio en el sentimiento interno.

R&D 부사장 겸 CMO인 Yehia Hashad가 Bausch + Lomb (BLCO)에 대한 Form 4를 제출했습니다. 2025년 7월 25일, 그는 회계 가격 $14.322,841 보통주를 거래 코드 F로 처분했으며, 이는 제한 주식 단위의 권리 확정으로 인해 발생한 급여세 의무를 충당하기 위해 주식이 단지 원천징수되었음을 나타냅니다. 이 처분은 공개 시장 판매가 아니며 경영진의 경제적 노출에 변화를 주지 않습니다. 원천징수 후 Hashad는 직접 116,739 BLCO 주식을 보유하고 있습니다. 파생 증권은 보고되지 않았습니다. 이 제출은 지속적인 내부자 대규모 소유를 나타내며 내부자 심리 변화보다는 일상적인 것으로 보입니다.

Le vice-président exécutif de la R&D et CMO Yehia Hashad a déposé un formulaire 4 pour Bausch + Lomb (BLCO). Le 25/07/2025, il a cédé 2 841 actions ordinaires à un prix comptable de 14,32 $ sous le code de transaction F, indiquant que les actions ont été retenues uniquement pour couvrir les obligations fiscales liées à la paie déclenchées par l’acquisition des unités d’actions restreintes. La cession n’était pas une vente sur le marché ouvert et ne modifie pas l’exposition économique du dirigeant. Après cette retenue, Hashad détient directement 116 739 actions BLCO. Aucun instrument dérivé n’a été déclaré. Ce dépôt indique une importante détention interne continue et semble être une opération routinière plutôt qu’un signe d’évolution du sentiment des initiés.

Der EVP für F&E und CMO Yehia Hashad reichte ein Formular 4 für Bausch + Lomb (BLCO) ein. Am 25.07.2025 veräußerte er 2.841 Stammaktien zu einem Buchpreis von 14,32 $ unter Transaktionscode F, was darauf hinweist, dass die Aktien ausschließlich zur Deckung von Lohnsteuerverpflichtungen einbehalten wurden, die durch die Vesting von Restricted Share Units ausgelöst wurden. Die Veräußerung war kein Verkauf am offenen Markt und ändert nicht die wirtschaftliche Beteiligung des Executives. Nach der Einbehaltung besitzt Hashad direkt 116.739 BLCO-Aktien. Es wurden keine Derivate gemeldet. Die Meldung signalisiert weiterhin eine erhebliche Insiderbeteiligung und erscheint routinemäßig, ohne auf eine Änderung der Insider-Stimmung hinzudeuten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Hashad Yehia

(Last) (First) (Middle)
C/O BAUSCH + LOMB CORPORATION
520 APPLEWOOD CRESCENT

(Street)
VAUGHAN A6 L4K4B4

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bausch & Lomb Corp [ BLCO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP of R&D and CMO
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares, No Par Value 07/25/2025 F 2,841(1) D $14.32 116,739 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of restricted share units.
/s/ Debra E. Levin, attorney-in-fact 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BLCO EVP Yehia Hashad report on the Form 4?

He reported 2,841 shares withheld to satisfy taxes upon RSU vesting on 07/25/2025.

Was the BLCO transaction an open-market sale?

No; code F indicates a tax-withholding transaction, not a discretionary sale.

How many BLCO shares does the executive now own?

After the transaction, Hashad directly holds 116,739 common shares.

At what price were the shares accounted for?

The shares were valued at $14.32 per share for withholding purposes.
Bausch + Lomb Corporation

NYSE:BLCO

BLCO Rankings

BLCO Latest News

BLCO Latest SEC Filings

BLCO Stock Data

4.85B
41.30M
88.41%
10.27%
0.53%
Medical Instruments & Supplies
Ophthalmic Goods
Link
Canada
VAUGHAN